Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niantong qufeng granules
- Development stage
- Phase 3
- Lead developer
- Chengdu Kangrui Pharmaceutical
- Administration
- Oral
01
Overview
Niantong Qufeng Granules (拈痛祛风颗粒) is a Traditional Chinese Medicine (TCM) compound granule developed for the treatment of acute gouty arthritis. The formulation is designed to dispel wind, eliminate dampness, and alleviate pain, targeting the inflammatory symptoms associated with gout flares. Developed by Chengdu Kangrui Pharmaceutical in collaboration with academic institutions, the drug has reached Phase III clinical trials in China to evaluate its efficacy and safety in reducing joint swelling and pain compared to standard care.
- Brand names
- Niantong Qufeng
- Other names
- 拈痛祛风颗粒Nian Tong Qu Feng granules
02
Targets
IL1B (Interleukin-1 beta)TNFA (Tumor necrosis factor alpha (soluble))XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on niantong qufeng granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niantong qufeng granules.